How Much Does Chromosome Testing Cost?

Chromosome testing ranges from a few hundred dollars for a basic analysis of miscarriage tissue to more than $9,000 for rapid whole-exome sequencing in a hospital setting. The exact price depends heavily on which test you need, why you need it, and whether insurance covers it. A standard karyotype ordered through a clinic might run $500 to $1,500 out of pocket, while a chromosomal microarray can cost roughly $700 to $2,000 or more. These figures shift depending on the lab, the clinical context, and your coverage, so understanding what drives the cost matters more than memorizing a single number.

Why There Is No Single Price Tag

“Chromosome testing” is an umbrella term that covers several distinct laboratory procedures, each designed to look at your genetic material at a different level of detail. A conventional karyotype examines your chromosomes under a microscope to spot large-scale abnormalities like missing or extra chromosomes, or big structural rearrangements. A chromosomal microarray (CMA) goes further, scanning across the genome for smaller deletions and duplications that a karyotype would miss. Fluorescence in situ hybridization (FISH) zeroes in on specific chromosomal regions and delivers results fast, sometimes within hours. And newer sequencing-based approaches can detect copy-number changes at even finer resolution. Each of these tests uses different technology, different reagents, and different levels of expert interpretation, which is why their costs differ so much.

The clinical reason for ordering the test also matters. A prenatal screen to check a fetus for Down syndrome follows a different workflow and regulatory pathway than a karyotype ordered for a couple experiencing recurrent miscarriage, or a FISH panel run on a bone marrow sample from someone with suspected leukemia. Labs price these tests differently because the specimen handling, turnaround time, and reporting complexity vary. A rapid FISH panel designed to detect specific chromosomal changes in leukemia, for instance, is optimized for speed and reliability on blood samples and serves a very different clinical purpose than a prenatal microarray.

Karyotyping Versus Microarray

For many people, the choice between a karyotype and a chromosomal microarray is where cost first becomes a practical question. A cost-effectiveness study of patients with unexplained developmental delay or intellectual disability found that a standard karyotype carried an average cost of about $11,000 per genetic diagnosis, largely because many karyotypes come back normal and do not yield an answer. Microarray testing, by contrast, picked up more diagnoses at an incremental cost of roughly $2,700 per additional diagnosis compared to karyotyping alone.¹ That study also found that running the two tests in sequence was most cost-efficient when the microarray was done first and a karyotype added only if needed.

The reason microarray tends to win on a per-diagnosis basis is that it catches smaller genetic changes that karyotyping simply cannot see. When a microarray turns up a variant of uncertain significance, testing both parents with their own microarrays can help clarify the finding, adding diagnoses at an incremental cost of about $4,200. And when the microarray itself comes back normal, targeted next-generation sequencing can still uncover a diagnosis, though at a steeper incremental cost of around $12,300.¹ These numbers reflect the cost per successful diagnosis, not the sticker price of the test itself, but they give you a useful sense of how much each layer of testing adds and what you get for the money.

Prenatal Chromosome Testing

Prenatal testing is where most expectant parents first encounter chromosome testing costs. The landscape has shifted considerably since noninvasive prenatal testing (NIPT) became widely available. NIPT is a blood draw from the pregnant person that screens for common chromosomal conditions by analyzing fragments of fetal DNA circulating in the mother’s blood. In the United States, the list price for NIPT from commercial labs has historically ranged from several hundred to over a thousand dollars, though many insurers now cover it for pregnancies considered high-risk, and some cover it for all pregnancies.

NIPT is a screening test, not a diagnostic one. If the screen comes back positive, your provider will recommend a confirmatory diagnostic test, usually amniocentesis or chorionic villus sampling (CVS). These invasive procedures involve collecting fetal cells directly, and the chromosome analysis performed on those cells gives a definitive answer. The procedure itself, the lab work, and the specialist consultation all contribute to the total bill, which can run into several thousand dollars before insurance. Research on how financing affects utilization of these tests showed that when Israel’s public health system lowered the eligibility age for covered amniocentesis to 35, testing rates jumped by about 35%, illustrating how much cost barriers shape who gets tested.²

The practical takeaway for expectant parents is to check with your insurer before the test is ordered. Many plans cover NIPT at no cost for pregnancies over a certain age or with other risk factors. If you are paying out of pocket, ask the lab about self-pay or cash-pay pricing, which is often lower than the list price billed to insurance.

Chromosome Testing After Pregnancy Loss

Couples experiencing recurrent miscarriage often face a battery of tests aimed at identifying a cause. Chromosome testing plays two roles here: testing the miscarriage tissue itself (products of conception) and testing the parents to see if either carries a balanced chromosomal rearrangement that could predispose to pregnancy loss.

A microarray analysis on products of conception has been reported at a self-pay cost of about $700, which is relatively modest compared to the full panel of blood tests, imaging, and hormone evaluations typically recommended for a recurrent pregnancy loss (RPL) workup. One study tallied the total self-pay cost of the standard RPL evaluation at roughly $3,290.³ Testing the miscarriage tissue with a microarray provided a probable or definite cause in a large percentage of cases, which can spare couples the expense and emotional burden of the full workup when the cause turns out to be a random chromosomal error in the embryo.

A decision analysis comparing selective versus universal RPL evaluation after a second miscarriage estimated the cost of a selective approach (testing miscarriage tissue first, then doing the full workup only if the tissue result suggested a non-random cause) at about $3,350, compared to $4,510 for universal testing of everyone. That selective strategy saved roughly $1,150 per patient and yielded even greater savings in older maternal age groups, where the odds of a random chromosomal error in the embryo are higher.⁴

As for karyotyping the parents themselves, some experts have questioned whether it is worth doing routinely. A study of parental karyotyping in recurrent pregnancy loss concluded that without a specific clinical indication, blanket karyotyping of couples can be expensive and labor-intensive while providing little useful information about fertility outcomes or the chance of a future live birth.⁵ In other words, parental karyotyping is most cost-effective when there is already a reason to suspect a chromosomal rearrangement in one partner, rather than as a routine checkbox.

Preimplantation Genetic Testing During IVF

For couples going through in vitro fertilization, preimplantation genetic testing for aneuploidy (PGT-A) adds a layer of chromosome analysis to the IVF cycle. PGT-A involves biopsying a few cells from each embryo before transfer and screening them for the correct number of chromosomes. The goal is to select embryos most likely to implant and develop normally, avoiding the transfer of embryos with chromosomal errors that would lead to failed implantation or miscarriage.

This convenience comes at a price. A cost-effectiveness analysis of PGT-A in fresh donor oocyte cycles found that adding PGT-A increased per-cycle costs by about $6,000.⁶ That figure covers the biopsy procedure and the genetic laboratory analysis. Whether PGT-A is cost-effective depends on the clinical scenario. For younger donors with high-quality embryos, the added cost may not improve outcomes enough to justify the expense. For older patients or those with a history of failed transfers, it may reduce the number of cycles needed and offset the upfront cost. The decision is personal and financial at the same time, and worth discussing with both your reproductive endocrinologist and your insurer, since PGT-A coverage varies widely across plans.

Rapid Whole-Exome Sequencing in Hospital Settings

At the more expensive end of the spectrum sits rapid whole-exome sequencing (rWES), which reads the protein-coding portions of a patient’s entire genome. This is typically used in urgent clinical settings, such as neonatal intensive care units, where a baby has a suspected genetic condition and a fast diagnosis could change treatment. The estimated cost per sample for rWES was about $9,340 in a study of pediatric patients with suspected single-gene disorders.⁷

That sounds steep, but the same study found that the total cost of sequencing 102 families (291 samples) was about $2.7 million, while the healthcare cost savings from faster diagnoses in just eight patients was estimated at more than $8 million, driven primarily by shorter hospital stays totaling 566 fewer inpatient days. The net savings across the whole cohort were estimated at over $5.3 million.⁷ Rapid sequencing is expensive per test, but in a hospital context where every day of NICU care costs thousands, a fast genetic diagnosis that changes clinical management can pay for itself many times over.

Insurance, Out-of-Pocket Costs, and Genetic Counseling

Whether you pay full price or next to nothing for chromosome testing depends largely on your insurance. Many private plans and Medicaid programs cover genetic testing when there is a documented clinical indication, such as a family history, abnormal screening results, or a provider’s referral for diagnostic evaluation. However, an analysis of commercial claims data for families of children evaluated for genetic conditions found that out-of-pocket costs did not differ based on how severe the child’s clinical presentation was, suggesting that insurance cost-sharing structures do not necessarily account for medical urgency when it comes to genetic tests.⁸

If your test requires prior authorization, your provider’s office usually handles the paperwork, but it is worth confirming that the specific lab your provider uses is in-network. Out-of-network genetic labs are a common source of surprise bills. Some labs offer patient assistance programs or flat-rate self-pay pricing that can be significantly lower than the amount billed to an insurer, so asking about this before the test is ordered is always worthwhile.

Genetic counseling is a related but separate cost that often accompanies chromosome testing. A genetic counselor helps you understand what the test can and cannot tell you, walks you through results, and helps with decision-making. An analysis of commercial insurance claims for cancer patients found that the median payment for a genetic counseling encounter was $118, and most patients paid nothing out of pocket, with an overall median out-of-pocket cost of $0. About 31% of patients had some out-of-pocket expense for counseling.⁹ While this data comes from cancer genetics, the billing codes and coverage patterns are similar for prenatal and other clinical genetics counseling. If you are offered genetic counseling as part of your testing process, it is generally an affordable addition, and many providers consider it essential for informed decision-making.

Emerging Alternatives That Could Lower Costs

The cost of chromosome-level analysis has been dropping as sequencing technology improves. One promising development is low-pass whole-genome sequencing (LP-WGS), which reads the entire genome at lower depth than clinical-grade sequencing but still catches copy-number changes comparable to what a microarray detects. Researchers have highlighted LP-WGS as a particularly important option for low- and middle-income countries, where the cost of a chromosomal microarray puts it out of reach for most of the population.¹⁰ In countries like Brazil, where microarray testing has been prohibitively expensive, LP-WGS could bring chromosome-level diagnostics to patients who currently have no access at all.

For specialized diagnostic needs, targeted approaches also keep costs down. In acute myeloid leukemia, for example, a streamlined FISH panel using just six probes has been developed to rapidly detect key chromosomal changes relevant to treatment decisions. This kind of targeted panel is far cheaper than sequencing the whole genome, and it delivers results fast enough to guide urgent clinical choices.¹¹ The broader trend in the field is toward matching the test to the clinical question as precisely as possible, which avoids paying for information you do not need.

Practical Steps to Manage Testing Costs

If you are facing chromosome testing and worried about the bill, a few concrete steps can help. First, ask your provider exactly which test is being ordered and why. “Genetic testing” on a bill could mean a targeted FISH analysis for a few hundred dollars or a comprehensive exome sequence for several thousand. Knowing the specific test lets you research its typical cost range and have a more informed conversation with your insurer.

Second, call your insurance company before the test is performed. Ask whether the specific CPT codes your provider plans to use are covered, whether the lab is in-network, and whether prior authorization is needed. Getting this in writing (or at least documenting the call) protects you if a claim is later denied.

Third, if you are uninsured or facing a high deductible, contact the lab directly and ask about self-pay pricing. Many genetic testing labs offer cash-pay rates that are substantially lower than the prices they bill to insurance companies. The $700 self-pay price for a microarray on miscarriage tissue, for instance, is a fraction of what some labs bill insurers for the same test.

Fourth, ask about patient financial assistance programs. Several large genetic testing companies offer programs that cap your out-of-pocket cost based on income, sometimes reducing a multi-thousand-dollar test to a few hundred dollars or less. Your genetic counselor, if you have one, is usually familiar with these programs and can point you in the right direction.

Finally, consider whether a less expensive test could answer your clinical question. If your provider recommends a microarray, ask whether a karyotype might suffice for your situation, or vice versa. The answer depends on what your provider is looking for, but the conversation itself is worth having. In some cases, a stepwise approach, starting with a cheaper test and escalating only if needed, saves money without sacrificing diagnostic accuracy. The cost-effectiveness research consistently supports this kind of tiered strategy over blanket ordering of the most comprehensive test available.